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Background/Aims
Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently 
overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap 
syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in guinea 
pigs. 
Methods
Male guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different 
doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 µg/kg of 
CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, 
incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of 
trimebutine and CRF treatment by fecal pellet output assay. 
Results
Different concentrations (1, 3, and 10 µg/kg) of rat/human CRF peptides was tested to establish the OS model in guinea pigs. CRF 
10 µg/kg was the most effective dose in the experimental OS model of guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment 
significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit 
while it reduced fecal pellet output in the CRF induced OS model. 
Conclusions
Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. 
Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients. 
(J Neurogastroenterol Motil 2018;24:669-675)
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Introduction  
Functional dyspepsia (FD) and irritable bowel syndrome (IBS) 
are common gastrointestinal (GI) diseases comprising 10% to 25% 
of the general population.1,2 However, there are several reports 
regarding frequent overlap between FD and IBS patients.3-5 Ac-
cording to the Rome III criteria, subjects with overlapping FD and 
IBS showed a significant increase in the severity of psychopathology 
as well as pathophysiological features.6-8 Studies demonstrated that 
stress is one of the primary factors associated with the onset, exacer-
bation, and reactivation of many GI disorders.9-11 Strong experimen-
tal evidence suggests that the central and peripheral corticotropin-
releasing factor (CRF) and its receptors facilitate stress related 
alterations in GI motility.12-15 Peripheral administration of CRF 
ligands demonstrated differential action on the upper and lower 
GI motility.16,17 CRF ligand was found to mimic changes similar to 
that induced by stress, while its antagonists alleviate stress-induced 
alteration of GI function.15-18 Therefore, peripheral CRF could 
be utilized to establish the animal model of the overlap syndrome 
(OS).18 
OS is an abnormal GI condition, where there are frequent 
overlap between FD and IBS patients.2,3 In other words, both hypo-
motility and hypermotility GI symptoms exist simultaneously in OS 
patients.2,3 Since most of the prokinetics are effective in a treating 
single disease condition, OS patients are therefore difficult to man-
age. Trimebutine might be an important drug candidate for OS 
patients, since it has been used for the treatment of various disorders 
including IBS, gastritis, and dyspepsia.19,20 
The mode of actions of trimebutine [3,4,5-trimethoxybenzoic 
acid 2(dimethylamino)-2-phenylbutylester] on the GI tract is multi-
faceted.21-23 It has unique spasmolytic activity and display significant 
non-selective agonist activity for intestinal opioid receptors μ, κ, 
and δ subtypes.21-23 It has been reported that trimebutine induces 
premature phase III of the migrating motor complex (MMC) in 
the intestine and also been demonstrated to modulate visceral sen-
sitivity.21 Moreover, it is likely to act on interstitial cells of Cajal, a 
well-known key player in the initiation and regulation of GI motility, 
as well as smooth muscles and enteric nerves.24 Few studies have re-
ported trimebutine as a multi-ion channel (Ca2+ and K+) regulator 
in the gut.19,25 Our previous study has confirmed OS model in con-
scious guinea pigs18 and hence it provides an opportunity to test the 
efficacy of trimebutine on this model. Therefore, we investigate the 
effect of trimebutine on a model of OS in guinea pigs to provide an 
experimental data to apply for the treatment of FD and IBS overlap.
Materials and Methods  
Preparation of Animals
Adult male Hartley guinea pigs (250-350 g; Orient Bio, Inc, 
Seoul, Korea) were acclimatized to their holding room (temperature 
controlled to 21 ± 1°C, 50 ± 10% humidity. A standard guinea 
pig diet and drinking water were provided ad libitum. All experi-
ments were conducted in accordance with the guide for the care and 
use of laboratory animals provided by the animal laboratory ethics 
committees of the Department of Laboratory Animal Medicine, 
Medical Research Center, Yonsei University College of Medicine. 
The study was performed in a manner to confirm with the Helsinki 
Declaration of 1975, as revised in 2000 and 2008, concerning Hu-
man and Animal Rights. This study was approved by the institu-
tional animal care and use committee (IACUC) of Yonsei Univer-
sity College of Medicine with IRB protocol number 2017-0073.
Chemicals and Drugs
The following chemicals and drugs were used: isotonic so-
dium chloride solution (Dai Han Pharmaceuticals, Seoul, Korea), 
charcoal (Sigma, Milwaukee, WI, USA), barium sulfate (Taejoon 
Pharmaceuticals, Seoul, Korea), rat/human (r/h) CRF (Peptide 
Institute, Inc, Osaka, Japan), and Trimebutine (Samil Pharmaceu-
ticals, Seoul, Korea). 
Experimental Design 1: Design of Overlap Syndrome 
Model of Guinea Pig 
The effect of CRF treatment on upper GI transit was tested by 
charcoal transit assay in fasted guinea pigs. R/h CRF peptides of 
different concentrations (1, 3, and 10 μg/kg) and vehicle (normal) 
were injected intraperitoneally in guinea pigs. After 30 minutes of 
stabilization, the guinea pigs received an intragastric administration 
of 3 mL of charcoal mixture (consisting of charcoal, barium, and 
normal saline mixed in a 1:2:6 ratio). Guinea pigs were euthanized 
after 10 minutes of incubation with the charcoal mix, and the upper 
GI transit was evaluated by assessing the migration of charcoal mix-
ture from the pylorus to the most distal point of the small intestine. 
The migration expressed as a percentage (%) of the total length of 
the small intestine (cm). The effect of CRF treatment on lower GI 
transit was measured by fecal pellet output (FPO) assay in non-
fasted guinea pigs. R/h CRF peptides of different concentrations 
(1, 3, and 10 μg/kg) and vehicle were injected intraperitoneally 
in guinea pigs. Each guinea pig was incubated into an individual 
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experimental cage and the cumulative number and weight of fecal 
pellets produced were measured and recorded for a total of 3 hours.
Experimental Design 2: The Effect of Trimebutine on 
Upper Gastrointestinal Transit in Overlap Syndrome 
Model
The effect of trimebutine on upper GI transit was tested by 
charcoal transit assay in fasted guinea pigs. Guinea pigs were 
pretreated with different concentrations (3, 10, and 30 mg/kg) of 
trimebutine and Control (0.9% saline) and incubated for 1 hour. 
Subsequently, each of these groups were administered 10 μg/kg of 
CRF or saline intraperitoneally. After 30 minutes of stabilization, 3 
mL of charcoal mixture was administered via an orogastric cannula. 
Guinea pigs were sacrificed after 10 minutes of incubation with 
charcoal mix, to evaluate the charcoal migration from the pylorus to 
the most distal point of the small intestine. 
Experimental Design 3: The Effect of Trimebutine on 
Lower Gastrointestinal Transit in Overlap Syndrome 
Model
The effect of trimebutine on lower GI transit was measured by 
FPO assay in non-fasted guinea pigs. Guinea pigs were pretreated 
with different concentrations (3, 10, and 30 mg/kg) of trimebutine 
and Control (0.9% saline) and incubated for 1 hour. There after 
each of these groups were administered 10 μg/kg of CRF or saline 
intraperitoneally. Each guinea pig was incubated into an individual 
experimental cage and the cumulative number and weight of fecal 
pellets produced were measured and recorded for total 4 hours. 
Statistical Methods
Results for each variable were expressed as percentage of 
control levels. Statistical analysis was performed using repeated 
measures ANOVA with post hoc comparison. In all tests analysis, 
statistical significance was assigned if P < 0.05 based on the mean. 
Values are means with standard error. All data were analyzed using 
SPSS version 12.0 for Windows software (SPSS Inc, Chicago, IL, 
USA).
Results  
As shown in Figure 1, the percent (%) charcoal migration (cm) 
in the control group was relatively similar to that of CRF 1 μg/
kg and 3 μg/kg treated groups. The higher dose of intraperitoneal 
CRF 10 μg/kg demonstrated significant inhibition of upper GI 
transit, compared to control (6.4 ± 2.2 vs 55.6 ± 19.9) (Fig. 1). In 
contrast, the effect of different doses of CRF peptide on lower GI 
transit showed a dose dependent acceleration of the FPO (Fig. 2). 
As compared to controls, intraperitoneal CRF dose of 3 μg/kg and 
10 μg/kg treated guinea pigs significantly increase the cumulative 
fecal pellets and weight (Fig. 2A and 2B). Intraperitoneal CRF 
dose of (10 μg/kg) treated guinea pigs significantly increase the cu-
mulative number of FPO (18.8 ± 6.9 vs 33.1 ± 11.9) and weight 
in grams (2.4 ± 0.8 vs 3.4 ± 2.0) compared to controls. The effect 
of different doses (3, 10, and 30 mg/kg) of trimebutine was tested 
independently in OS model of guinea pigs. As shown in Figure 3, 
trimebutine (3, 10, and 30 mg/kg) treated guinea pigs significantly 
increased (46.2 ± 14.6; 53.8 ± 11.6; 77.7 ± 10.5 vs 6.4 ± 2.2) 
the upper GI transit compared to the most effective dose (10 μg/
kg) of CRF in the OS model (Fig. 3). Contrary to the effect on up-
per GI transit, different doses of trimebutine significantly decreased 
the cumulative number of FPO (18.5 ± 17.8; 15.5 ± 10.7; 12.3 
± 10.4 vs 33.1 ± 11.9) and weight (2.4 ± 2.0; 1.8 ± 1.2; 1.5 ± 
1.2 vs 3.4 ± 2.0), compared to only the CRF 10 μg/kg treated OS 
model (Fig. 4A and 4B). 
Discussion  
Several studies demonstrated that patients with one of the GI 
diseases often suffered from a second overlapping disease.26-30 A 
recent population based study from China based on the Rome III 
criteria showed 33.0% overlap of patients of IBS in FD patients and 
45.9% of FD in IBS patients.27 Again a study from the Japanese 
general population showed the prevalence of overlaps of FD and/
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Figure 1. The effect of different doses of corticotropin-releasing fac-
tor (CRF) peptide on upper gastrointestinal transit in guinea pigs. 
Data represents mean ± SEM (n = 6/group). *P < 0.05 in com-
parison to controls. 
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or IBS in GERD, GERD and/or IBS in FD, and GERD and /or 
FD in IBS was 46.9%, 47.6%, and 34.4% respectively.2 Apart from 
the high prevalence, our previous study, as well as several other re-
ports have suggested a health related decline in quality of life (HR-
QOL) and higher severity symptom scores among patients of FD-
IBS overlap.2,26-30 Despite the higher incidence, severity symptom 
scores and deteriorating HR-QOL among overlap patients, there 
is no successful animal model with some evidence and construct 
validity for the human syndrome. In this series, our previous study 
successfully demonstrated CRF induced OS in the model of 
guinea pigs that mimic more than one symptom of humans.18 The 
curative aspect of OS is complex and hence the primary concern 
has been the development of efficient prokinetic agents. Several 
studies suggested trimebutine as an effective GI modulator and its 
common use in the treatment of functional bowel disorders, includ-
ing IBS and postoperative ileus.20-23 Trimebutine moiety is a non-
competitive spasmolytic agent that exhibit substantial agonist action 
on intestinal opioid receptors including μ and κ.22,23 In animals and 
humans, trimebutine is metabolized in the liver into an active de-
rivative called N-desmethyl-trimebutine, which blocks the sodium 
channels activity and also display a potent local anesthetic effect.22 
This study focused on the treatment aspects and dichotomic action 
of trimebutine that provide us an opportunity to test this drug in 
the experimental OS model. Remarkably, in our study trimebutine 
modulates the GI motility in CRF induced OS model of guinea 
pigs. Trimebutine significantly reverses the CRF induced decrease 
of upper GI transit and optimize the motility similar to that of the 
healthy control. Similarly, it also reverses the CRF induced increase 
of lower GI transit and effectively moderate the motility similar to 
that of healthy controls. Our study corroborates the earlier findings 
that trimebutine may be a reliable modulator of GI motility, and a 
potential candidate for the treatment of both hypermotility and hy-
pomotility disorders.20,23 Most of the studies regarding the mecha-
nism of action of trimebutine indicated the involvement of the gas-
tric MMC.21,31 Trimebutine accelerates gastric emptying, it brings 
premature phase III of the MMC in the intestine and regulates the 
contractile activity of the colon.21,32 Many naturally occurring pep-
tide modulators control the MMC in the enteric nervous system, 
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Figure 2. Effect of different doses of corticotropin-releasing factor (CRF) peptide on the lower gastrointestinal transit in guinea pigs. (A) The ef-
fect of different concentrations of CRF on the number of cumulative fecal pellets. (B) The effect of different concentrations of CRF on the cumu-
lative fecal pellet output (FPO) weight (g). Data represents mean ± SEM (n = 6/group). *P < 0.05, **P < 0.01 in comparison to controls. 
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Figure 3. Effect of different doses of trimebutine on the upper gas-
trointestinal transit in overlap syndrome model of guinea pigs. Data 
represents mean ± SEM (n = 6/group). *P < 0.05, **P < 0.01 in 
comparison to corticotropin-releasing factor (CRF) 10 μg/kg only.
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and among them the opioid receptor-dependent influences were the 
most significant.33-35 Trimebutine also acts through the release of GI 
peptides such as motilin, vasoactive intestinal peptide, gastrin and 
glucagon.21 Motilin and other compounds involving motilin recep-
tors appeared to play a significant role in the initiation of phase III 
of the MMC in man and dogs, but not in pigs.32 Reports indicate 
the pivotal role of serotonin and serotonin receptors in controlling 
the MMC.36 On the other hand, the effect of trimebutine on stress-
induced changes in gut motility presented significant decrease in 
the duration of phase III of the MMC.37,38 
Recently, several improved versions of trimebutine have been 
developed, such as nitro-arginine based trimebutine salt with the 
capability to release nitric oxide, a gaseous mediator.39 The nitric ox-
ide released from the nitro-arginine interacts with the opioid agonist 
to potentiate its analgesic activity.39 Wallace et al40 developed another 
innovative trimebutine salt capable of releasing in vivo hydrogen 
sulfide, a gaseous mediator known to reduce nociception as well as 
being involved in multilevel regulation of physiological and patho-
logical functions in mammalian tissues.41 
We do acknowledge that our study has limitations. The main 
limitation of our method was the indirect evaluation of colonic tran-
sit time by measuring the cumulative number and weight of fecal 
pellets. In conclusion, trimebutine has been demonstrated to be ef-
fective on both upper GI and lower GI motor function in peripheral 
CRF induced OS. Therefore, trimebutine may be an important 
drug for the treatment of OS between FD and IBS patients. There-
fore, further studies are needed to clarify the mechanistic action of 
trimebutine in OS model. 
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